Media Summary: This episode takes a deep dive into the advanced Presenter: Dr. Aniko Szabo, PhD, Associate Professor in the Division of Biostatistics This talk will discuss From Objectives to Outcomes: A Trialist's Guide to Key

63 Statistical Considerations In Phase - Detailed Analysis & Overview

This episode takes a deep dive into the advanced Presenter: Dr. Aniko Szabo, PhD, Associate Professor in the Division of Biostatistics This talk will discuss From Objectives to Outcomes: A Trialist's Guide to Key Janet Wittes, Eric Leifer, Bill Abraham, and Mitchell Psotka join the podcast to discuss all-things by Dr Weili He and Dr. Mark Levenson A Real-World Evidence (RWE) scientific working group of the American

Photo Gallery

63 - Statistical Considerations in Phase 3 (S5E3)
Statistical Considerations for Phase II Clinical Trials and Adaptive Designs
Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring
Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring (中
Statistical Considerations in Grant Writing
Statistical Considerations for Premarketing Risk Assessment
CTTG Lecture 26 - Statistical considerations with Dr. Robert Balshaw
Ep.3: Statistical Considerations in Heart Failure Research
Methodological and statistical considerations in implementation science
Statistical considerations in Design 3. Normal curve
Statistical considerations in design : 1. Introduction
Statistical considerations in the clinical development of novel cancer therapies
View Detailed Profile
63 - Statistical Considerations in Phase 3 (S5E3)

63 - Statistical Considerations in Phase 3 (S5E3)

This episode takes a deep dive into the advanced

Statistical Considerations for Phase II Clinical Trials and Adaptive Designs

Statistical Considerations for Phase II Clinical Trials and Adaptive Designs

J. Jack Lee, PhD, DDS.

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring

Jack Lee, PhD, DDS.

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring (中

Statistical Considerations for Phase III Randomized Trials, Interim Analysis, and Data Monitoring (中

Jack Lee, PhD, DDS.

Statistical Considerations in Grant Writing

Statistical Considerations in Grant Writing

Presenter: Dr. Aniko Szabo, PhD, Associate Professor in the Division of Biostatistics This talk will discuss

Statistical Considerations for Premarketing Risk Assessment

Statistical Considerations for Premarketing Risk Assessment

This presentation described important

CTTG Lecture 26 - Statistical considerations with Dr. Robert Balshaw

CTTG Lecture 26 - Statistical considerations with Dr. Robert Balshaw

From Objectives to Outcomes: A Trialist's Guide to Key

Ep.3: Statistical Considerations in Heart Failure Research

Ep.3: Statistical Considerations in Heart Failure Research

Janet Wittes, Eric Leifer, Bill Abraham, and Mitchell Psotka join the podcast to discuss all-things

Methodological and statistical considerations in implementation science

Methodological and statistical considerations in implementation science

Methodological and

Statistical considerations in Design 3. Normal curve

Statistical considerations in Design 3. Normal curve

Statistical considerations

Statistical considerations in design : 1. Introduction

Statistical considerations in design : 1. Introduction

Statistical considerations

Statistical considerations in the clinical development of novel cancer therapies

Statistical considerations in the clinical development of novel cancer therapies

... some uh

ASA Biopharm Webinar: Statistical Considerations for Evaluation of Fit-for-Purpose Real-World Data

ASA Biopharm Webinar: Statistical Considerations for Evaluation of Fit-for-Purpose Real-World Data

by Dr Weili He and Dr. Mark Levenson A Real-World Evidence (RWE) scientific working group of the American